Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: A randomised clinical trial

• Published in: The European respiratory journal Vol. 58; no. 2; p. 2002535
• Main Authors: Wittermans, Esther, Vestjens, Stefan Mt, Spoorenberg, Simone Mc, Blok, Willem L, Grutters, Jan C, Janssen, Rob, Rijkers, Ger T, Smeenk, Frank Wjm, Voorn, Paul, van de Garde, Ewoudt Mw, Bos, Willem Jan W
• Format: Journal Article
• Language: English
• Published: England 01.08.2021
• ISSN: 0903-1936; 1399-3003
• DOI: 10.1183/13993003.02535-2020

Adjunctive intravenous corticosteroid treatment has shown to reduce length of stay (LOS) in adults hospitalised with community-acquired pneumonia (CAP). We aimed to assess the effect of oral dexamethasone on LOS and whether this effect is disease severity dependent. In this multicentre, stratified randomised, double-blind, placebo-controlled trial, immunocompetent adults with CAP were randomly assigned (1:1 ratio) to receive oral dexamethasone (6 mg once daily) or placebo for 4 days in four teaching hospitals in the Netherlands. Randomisation (blocks of four) was stratified by CAP severity (pneumonia severity index class I-III and IV-V). The primary outcome was LOS. This study is registered with ClinicalTrials.gov ( . Between December 2012 and November 2018, 401 patients were randomised to receive dexamethasone (n=203) or placebo (n=198). Median LOS was shorter in the dexamethasone group (4.5 days (95% CI 4.0-5.0)) than in the placebo group (5.0 days (95% CI 4.6-5.4); p=0.033). Within both CAP severity subgroups, differences in LOS between treatment groups were not statistically significant. Secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) 14 (7%), p=0.030), 30-day mortality did not differ between groups. In the dexamethasone group rate of hospital readmission tended to be higher (20 (10%) 9 (5%); p=0.051) and hyperglycaemia (14 (7%) 1 (1%); p=0.001) was more prevalent. Oral dexamethasone reduced LOS and ICU admission rate in adults hospitalised with CAP. It remains unclear for which patients the risk-benefit ratio is optimal.